EUVIMEDEUVIMED entdecken
Open Access

Germline EGFR Mutations and Familial Lung Cancer

Geoffrey R Oxnard iD, Ruthia Chen iD, Jennifer C Pharr, Diane R Koeller iD, Arrien A Bertram iD, Suzanne E Dahlberg iD, Irene Rainville iD, Kate Shane-Carson iD, Kelly A Taylor, Alicia Sable-Hunt, Lynette M Sholl iD, Craig C Teerlink und 11 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.23.01372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Geoffrey R Oxnard und 22 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The genomic underpinnings of inherited lung cancer risk are poorly understood. This prospective study characterized the clinical phenotype of patients and families with germline EGFR pathogenic variants (PVs). METHODS The Investigating Hereditary Risk from T790M study (ClinicalTrials.gov identifier: NCT01754025 ) enrolled patients with lung cancer whose tumor profiling harbored possible germline EGFR PVs and their relatives, either in person or remotely, providing germline testing and follow-up. RESULTS A total of 141 participants were enrolled over a 5-year period, 100 (71%) remotely. Based upon previous genotyping, 116 participants from 59 kindreds were tested for EGFR T790M, demonstrating a pattern of Mendelian inheritance with variable lung cancer penetrance. In confirmed or obligate carriers of a germline EGFR PV from 39 different kindreds, 50/91 (55%) were affected with lung cancer with 34/65 (52%) diagnosed by age 60 years. Somatic testing of lung cancers in carriers revealed that 35 of 37 (95%) had an EGFR driver comutation. Among 36 germline carriers without a cancer diagnosis, 15 had computed tomography (CT) imaging and nine had lung nodules, including a 28-year-old with >10 lung nodules. Given geographic enrichment of germline EGFR T790M in the southeast United States, genome-wide haplotyping of 46 germline carriers was performed and identified a 4.1-Mb haplotype shared by 41 (89%), estimated to originate 223-279 years ago. CONCLUSION To our knowledge, this is the first prospective description of familial EGFR-mutant lung cancer, identifying a recent founder germline EGFR T790M variant enriched in the Southeast United States. The high prevalence of EGFR-driver lung adenocarcinomas and lung nodules in germline carriers supports effort to identify affected patients and family members for investigation of CT-based screening for these high-risk individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansMiddle AgedAdultProspective StudiesErbB ReceptorsMutationProtein Kinase InhibitorsGerm-Line MutationLung

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • Ohio State University Medical Center, Columbus, OH.
  • Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • Addario Lung Cancer Medical Institute (ALCMI), San Carlos, CA.
  • Brigham and Women's Hospital, Boston, MA.
  • Huntsman Cancer Center, Salt Lake City, UT.

ORCID-Profile: Geoffrey R Oxnard, Ruthia Chen, Diane R Koeller, Arrien A Bertram, Suzanne E Dahlberg, Irene Rainville, Kate Shane-Carson, Lynette M Sholl, Lisa A Cannon-Albright, Patrícia Ashton-Prolla, Pasi A Jänne, David P Carbone, Georgia L Wiesner, Judy E Garber

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Oxnard, G. R., Chen, R., Pharr, J. C., Koeller, D. R., Bertram, A. A., Dahlberg, S. E., Rainville, I., Shane-Carson, K., Taylor, K. A., Sable-Hunt, A., Sholl, L. M., Teerlink, C. C., Thomas, A., Cannon-Albright, L. A., Fay, A. P., Ashton-Prolla, P., Yang, H., Salvatore, M. M., Addario, B. J., …, & Garber, J. E. (2023). Germline EGFR Mutations and Familial Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01372

Vancouver

Oxnard GR, Chen R, Pharr JC, Koeller DR, Bertram AA, Dahlberg SE, et al. Germline EGFR Mutations and Familial Lung Cancer. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.01372

BibTeX
@article{Oxnard2023,
  author = {Oxnard, Geoffrey R and Chen, Ruthia and Pharr, Jennifer C and Koeller, Diane R and Bertram, Arrien A and Dahlberg, Suzanne E and Rainville, Irene and Shane-Carson, Kate and Taylor, Kelly A and Sable-Hunt, Alicia and Sholl, Lynette M and Teerlink, Craig C and Thomas, Alun and Cannon-Albright, Lisa A and Fay, André P and Ashton-Prolla, Patrícia and Yang, Hao and Salvatore, Mary M and Addario, Bonnie J and Jänne, Pasi A and Carbone, David P and Wiesner, Georgia L and Garber, Judy E},
  title = {Germline EGFR Mutations and Familial Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.23.01372}
}
Kostenlos starten →